Geode Capital Management LLC Grows Stake in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Geode Capital Management LLC boosted its holdings in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 6.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,030,443 shares of the company’s stock after purchasing an additional 124,782 shares during the quarter. Geode Capital Management LLC owned about 2.24% of Caribou Biosciences worth $3,980,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in CRBU. Bank of New York Mellon Corp raised its position in shares of Caribou Biosciences by 14.1% during the second quarter. Bank of New York Mellon Corp now owns 308,273 shares of the company’s stock valued at $506,000 after buying an additional 38,098 shares during the last quarter. American Century Companies Inc. increased its holdings in Caribou Biosciences by 15.2% in the 2nd quarter. American Century Companies Inc. now owns 125,029 shares of the company’s stock valued at $205,000 after acquiring an additional 16,530 shares during the last quarter. Bruce & Co. Inc. lifted its stake in Caribou Biosciences by 50.0% in the 2nd quarter. Bruce & Co. Inc. now owns 300,000 shares of the company’s stock worth $492,000 after purchasing an additional 100,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Caribou Biosciences by 25.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock valued at $4,302,000 after purchasing an additional 536,162 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Caribou Biosciences in the second quarter worth about $2,432,000. 77.51% of the stock is owned by hedge funds and other institutional investors.

Caribou Biosciences Price Performance

Shares of NASDAQ CRBU opened at $1.72 on Monday. Caribou Biosciences, Inc. has a 1-year low of $1.50 and a 1-year high of $8.33. The business’s 50 day moving average is $2.03 and its two-hundred day moving average is $2.00. The stock has a market capitalization of $155.75 million, a P/E ratio of -1.04 and a beta of 2.27.

Caribou Biosciences (NASDAQ:CRBU) last announced its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.06. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The firm had revenue of $2.02 million during the quarter, compared to analysts’ expectations of $3.37 million. As a group, equities research analysts anticipate that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CRBU has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Citigroup lowered their target price on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 26th. Four research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $10.20.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.